Immune Cell

Cell Therapy Enhances Survival in Lung Cancer Treatment

In a 5-year retrospective study, CAPRI cell therapy alongside chemotherapy improved survival outcomes for non-small-cell lung cancer (NSCLC) patients compared to chemotherapy alone. Patients treated with CAPRI showed higher immune marker expression, indicating a robust immune response. This combination therapy resulted in significantly longer overall survival and progression-free survival, with manageable side effects, suggesting CAPRI's potential as an effective adjuvant immunotherapy for NSCLC.

Download File:immune-07

 

CAPRI: A Promising Adoptive Cell Therapy for Cancer

Adoptive cell therapy (ACT) with cascade-primed immune cells (CAPRI) is an emerging technique showing promise in cancer treatment. Studies suggest that immune cells play a crucial role in combating cancer, with certain genes and the presence of immune cells in tumors being linked to better patient outcomes. CAPRI, a novel ACT method, involves stimulating the patient's immune cells to more effectively target and destroy cancer cells. Early results from patient case series indicate that CAPRI could be more effective than traditional ACT methods, meriting further investigation.

Download File:immune-06

 

HLA-Haploidentical Donor Immune Cell Infusion Safe in Childhood Cancer

A study at Sun Yat-sen University Cancer Center found HLA-haploidentical donor immune cell infusion (HDICI) to be safe for treating childhood malignancies. Over one year, 12 children, mostly with high-risk neuroblastoma, received 92 HDICIs without serious adverse effects or graft versus host disease. Some patients experienced fever and mild emotional changes. Follow-up showed two neuroblastoma patients progressed, seven remained in complete remission, and one EBV-LPD patient improved, indicating HDICI’s potential as a safe treatment option.

Download File:immune-05

 

Intrapleural mCIK Cell Therapy Eases Symptoms in CDC Metastasis Patient

A 33-year-old male with aggressive kidney cancer (CDC) experienced symptom relief and reduced pleural fluid after treatment with modified cytokine-induced killer cells, indicating a promising therapy for pleural metastasis.

Download File:immune-04

 

CAPRI Method: A Novel Cancer Immunotherapy-

The CAPRI method uses patient-derived monocytes to activate T cells for attacking cancer. This treatment doesn't need tumor cells or specific peptides. It quickly creates powerful immune cells capable of cancer destruction, with evidence of efficacy in both mice and a small group of breast cancer patients, showing improved 5-year survival rates. The process is safe, fast, and works against various cancers.

Download File:immune-03

 

CD4 T cells-

CD4 T cells play a critical role in regulating CD8 T-cell responses during chronic viral infection. Several studies in animal models and humans have shown that the absence of CD4 T-cell help results in severe dysfunction of virus-specific CD8 T cells.

These results suggest that CD4 T-cell immunotherapy alone or in conjunction with the blockade of inhibitory receptors may be a promising approach for treating CD8 T-cell dysfunction in chronic infections and cancer.

Download File:immune-02

 

Cancer Immunotherapy-

Cancer cells have genetic and cellular changes that allow the immune system to recognize and attack them with T-cell responses. However, this is just one step in the Cancer-Immunity Cycle, which balances recognition of nonself with the prevention of autoimmunity. Inhibitory signals like PD-L1 can hinder immune response, but new cancer immunotherapy can specifically target and overcome this inhibition, potentially expanding anticancer immune responses. Suppressive factors in the tumor microenvironment may explain the limited success of past immune-based therapies, but combining therapies targeting different steps of the cycle may increase effectiveness. Clinical data suggests that cancer immunotherapy will likely become an important part of cancer treatment.

Download File:immune-01